Novo Nordisk shares dropped 8% on Tuesday after its rival Eli Lilly and Co. published positive trial results.The United States medicine company reported last week positive results from a late-stage trial regarding its oral weight loss drug orforglipron. Following this development, Novo Nordisk marked a...
Novo Nordisk shares tumbled by more than 18% on Friday after the company reported below-expected results from a phase three trial for its CagriSema weight loss drug.The drug combines semaglutide, also found in the company's other popular obesity drug, Wegovy, and the amylin analog,...
Novo Nordisk announced Monday that it plans to commit 8.5 billion Danish kroner (around $1.23 billion) to construct a new facility in Odense, Denmark.According to the statement, the 40,000 m² state-of-the-art facility will support rare disease treatments like hemophilia, utilizing advanced...
Novo Nordisk shares plummeted more than 2% on Friday after it was learned that a preprint published on medRxiv claims there is a link between Ozempic and a rare vision condition.The new study was conducted by a group of scholars from Norway and Denmark and claims diabetes patients...
The United Kingdom's Prescription Medicines Code of Practice Authority (PMCPA) publicly reprimanded Novo Nordisk, the manufacturer of diabetes drug Ozempic and weight-loss treatment Wegovy, for failing to adequately disclose £7.8 million in payments and other benefits provided to patients,...
United States Senator and Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), Bernie Sanders, announced that Novo Nordisk CEO Lars Jorgensen (pictured) will testify voluntarily in early September about the "outrageously high prices" charged in the US for the...
Shares of Danish biotechnology research business, Zealand Pharma A/S, skyrocketed 30% on Monday after sharing that its trial liver disease treatment was effective in 83% of the people tested, thus positioning the company as a potential contender in the growing weight-loss market.
The drug...
Novo Holdings A/S, the holding company for pharmaceutical Novo Nordisk, announced on Monday that it is acquiring Catalent Inc. for $16.5 billion in cash at $63.50 per share, representing a 16.5% premium. The deal is expected to close toward the end of 2024.
Novo Holdings said the transaction is...
Novo Nordisk A/S will invest €2.1 billion in a production plant in France, RTL Info reported on Thursday. With this investment, the company intends to increase production of its Ozempic and Wegovy drugs, which have been in increasing demand in recent months as they have become widely used for...
Novo Nordisk A/S announced on Friday that it is planning to invest 42 billion Danish kroner ($6 billion) in 2023 to expand manufacturing facilities in Kalundborg, Denmark, with the goal of creating roughly 800 new jobs.
The investment will see Novo Nordisk improve its ability to meet future market...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
